Establishment of novel molecular targeted therapy focused on apoptosis induction in ovarian clear cell adenocarcinoma

2016 Fiscal Year Final Research Report

• Project/Area Number: 15H06173
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Obstetrics and gynecology
• Research Institution: The University of Tokyo
• Principal Investigator: Kashiyama Tomoko 東京大学, 医学部附属病院, 助教 (70755719)
• Project Period (FY): 2015-08-28 – 2017-03-31
• Keywords: PI3K/mTOR阻害薬 / 卵巣明細胞癌 / アポトーシス / 婦人科悪性腫瘍 / 卵巣癌

Outline of Final Research Achievements

We confirmed that a PI3K / mTOR inhibitor suppressed the growth signal and showed the antitumor effect in a concentration-dependent manner in ovarian clear cell adenocarcinoma cell line. In addition, the the PI3K/mTOR inhibitor leaded apoptosis in ovarian clear cell adenocarcinoma cell lines with wild type TP53 more effectively than that with TP53 mutation. The absence of TP53 mutation may be a promising biomarker for using PI3K / mTOR inhibitors for patients with ovarian clear cell adenocarcinoma. We are investigating whether combination with PI3K/mTOR inhibitor and other molecular target drugs or anticancer drugs can induce more efficient apoptosis, and MDM 2 inhibitors and MEK inhibitors are considered to be promising candidates.

Free Research Field

分子標的薬